Beverly A. Riley

Radiotherapy toxicities: mechanisms, management, and future directions

Senescence drives immunotherapy resistance by inducing an immunosuppressive tumor microenvironment

Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non–small-cell lung cancer

Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: How do protons compare with other conformal techniques?